Long-acting inhaled beta(2)-agonist therapy in asthma

Am J Respir Crit Care Med. 2001 Sep 15;164(6):923-32. doi: 10.1164/ajrccm.164.6.2010107.
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Administration, Topical
  • Adrenergic beta-Agonists / administration & dosage*
  • Adult
  • Age Factors
  • Albuterol / administration & dosage
  • Albuterol / analogs & derivatives*
  • Androstadienes / administration & dosage
  • Anti-Asthmatic Agents / administration & dosage*
  • Anti-Inflammatory Agents / administration & dosage
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Beclomethasone / administration & dosage
  • Bronchial Provocation Tests
  • Bronchodilator Agents / administration & dosage*
  • Budesonide / administration & dosage
  • Child
  • Child, Preschool
  • Drug Interactions
  • Drug Therapy, Combination
  • Ethanolamines / administration & dosage
  • Fluticasone
  • Formoterol Fumarate
  • Glucocorticoids
  • Humans
  • Meta-Analysis as Topic
  • Polymorphism, Genetic
  • Randomized Controlled Trials as Topic
  • Receptors, Adrenergic, beta-2 / drug effects*
  • Receptors, Adrenergic, beta-2 / genetics
  • Receptors, Glucocorticoid / drug effects
  • Receptors, Glucocorticoid / genetics
  • Respiratory Therapy*
  • Salmeterol Xinafoate
  • Time Factors

Substances

  • Adrenergic beta-Agonists
  • Androstadienes
  • Anti-Asthmatic Agents
  • Anti-Inflammatory Agents
  • Bronchodilator Agents
  • Ethanolamines
  • Glucocorticoids
  • Receptors, Adrenergic, beta-2
  • Receptors, Glucocorticoid
  • Budesonide
  • Salmeterol Xinafoate
  • Fluticasone
  • Beclomethasone
  • Albuterol
  • Formoterol Fumarate